Alector Q1 rev $24.5M, net loss $44.6M; latozinemab shows 54% disease progression delay in FTD-C9orf72

Alector, Inc.

2023-Q1 EPS reported -$0.54 revenue$24,474,000

Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.
Cash, cash equivalents, and marketable securities $868.6M; sufficient to fund operations into mid-2024.
INFRONT-2 Phase 2: latozinemab in FTD-C9orf72 showed ~54% annual delay in disease progression vs matched control.
AL101 Phase 1 enrollment completed; data expected H2 2022. AL044 Phase 1 to initiate H2 2022.
Gary Romano, M.D., Ph.D., joins as CMO on May 23, 2022; Marc Grasso, M.D., joined as CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.